Literature DB >> 28391791

Molecular and Metabolic Imaging in Multiple Sclerosis.

Marcello Moccia1, Olga Ciccarelli2.   

Abstract

Multiple sclerosis is a multifactorial disease with heterogeneous pathogenetic mechanisms, which deserve to be studied to evaluate new possible targets for treatments and improve patient management. MR spectroscopy and PET allow assessing in vivo the molecular and metabolic mechanisms underlying the pathogenesis of multiple sclerosis. This article focuses on the relationship between these imaging techniques and the biologic and chemical pathways leading to multiple sclerosis pathology and its clinical features. Future directions of research are also presented.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MR imaging; Metabolic; Molecular; Multiple sclerosis; PET; Spectroscopy

Mesh:

Year:  2017        PMID: 28391791     DOI: 10.1016/j.nic.2016.12.005

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  10 in total

Review 1.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Imaging outcome measures for progressive multiple sclerosis trials.

Authors:  Marcello Moccia; Nicola de Stefano; Frederik Barkhof
Journal:  Mult Scler       Date:  2017-10       Impact factor: 6.312

Review 3.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

4.  Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?

Authors:  Daniele Belvisi; Matteo Tartaglia; Giovanna Borriello; Viola Baione; Sebastiano Giuseppe Crisafulli; Valeria Zuccoli; Giorgio Leodori; Antonio Ianniello; Gabriele Pasqua; Patrizia Pantano; Alfredo Berardelli; Carlo Pozzilli; Antonella Conte
Journal:  Biomedicines       Date:  2022-01-21

5.  Fibrin-targeting molecular MRI in inflammatory CNS disorders.

Authors:  Johannes Lohmeier; Rafaela V Silva; Anna Tietze; Matthias Taupitz; Takaaki Kaneko; Harald Prüss; Friedemann Paul; Carmen Infante-Duarte; Bernd Hamm; Peter Caravan; Marcus R Makowski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-04       Impact factor: 10.057

6.  In Vivo Proton Exchange Rate (kex ) MRI for the Characterization of Multiple Sclerosis Lesions in Patients.

Authors:  Haiqi Ye; Mehran Shaghaghi; Qianlan Chen; Yan Zhang; Sarah E Lutz; Weiwei Chen; Kejia Cai
Journal:  J Magn Reson Imaging       Date:  2020-09-24       Impact factor: 4.813

7.  Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations.

Authors:  Andrew A Maudsley; Ovidiu C Andronesi; Peter B Barker; Alberto Bizzi; Wolfgang Bogner; Anke Henning; Sarah J Nelson; Stefan Posse; Dikoma C Shungu; Brian J Soher
Journal:  NMR Biomed       Date:  2020-04-29       Impact factor: 4.044

8.  Gray matter blood-brain barrier water exchange dynamics are reduced in progressive multiple sclerosis.

Authors:  Ian J Tagge; Valerie C Anderson; Charles S Springer; Manoj K Sammi; Dennis N Bourdette; Rebecca I Spain; William D Rooney
Journal:  J Neuroimaging       Date:  2021-08-06       Impact factor: 2.324

Review 9.  Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.

Authors:  Matteo Bauckneht; Selene Capitanio; Stefano Raffa; Luca Roccatagliata; Matteo Pardini; Caterina Lapucci; Cecilia Marini; Gianmario Sambuceti; Matilde Inglese; Paolo Gallo; Diego Cecchin; Flavio Nobili; Silvia Morbelli
Journal:  EJNMMI Radiopharm Chem       Date:  2019-04-08

Review 10.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.